NEW YORK (GenomeWeb) – Pacific Biosciences has received a $10 million payment from Roche for hitting a development milestone that is part of the commercialization and license agreement the companies struck in 2013, according to a PacBio filing with the US Securities and Exchange Commission.

PacBio didn't disclose what development milestone had been met, but noted that it may receive up to $30 million in the future for reaching additional development milestones. It said that the payment will be recorded as contractual revenue in its third quarter financial statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.